skip to main content

TAF vs TDF Renal Safety CKD — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateChronic Kidney DiseaseTAF vs TDF Renal Safety CKDESENeph

A 40-year-old man with CKD G3a and hepatitis B (HBsAg positive, HBeAg negative, HBV DNA suppressed on Tenofovir Alafenamide) asks whether TAF is preferred over TDF in CKD. What is the key difference?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — TAF (Tenofovir Alafenamide) achieves higher intracellular drug concentrations at 90% lower plasma levels than TDF (Tenofovir Disoproxil Fumarate), resulting in significantly less renal tubular toxicity and bone density loss – TAF is preferred in CKD

TDF is associated with proximal tubular toxicity (Fanconi syndrome), reduced GFR, and bone density loss due to high plasma tenofovir concentrations exposing the proximal tubule. TAF is a prodrug that is primarily activated intracellularly (in target cells), achieving 90% lower plasma tenofovir levels. This dramatically reduces renal and bone toxicity while maintaining equivalent antiviral efficacy. BHIVA 2021 and EASL 2024 guidelines recommend TAF over TDF for HBV treatment in patients with CKD or osteoporosis risk factors. TAF does not require renal dose adjustment (unlike TDF).

Reference: BHIVA 2021; EASL 2024 – HBV; BNF – TAF vs TDF